Peter Pfreundschuh compensation by year
Y-mAbs Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $252,083 |
| Bonus | $0 |
| Stock awards | $573,620 |
| Option awards | $1,580,609 |
| Non-equity incentive | $98,405 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $2,504,717 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Y-mAbs Therapeutics, Inc. DEF 14A filed May 30, 2025, accession 0001558370-25-008299, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Y-mAbs Therapeutics, Inc. filed document, accession 0001558370-25-008299. Every figure is read from that document and cited to the page and table it appears in. Filed May 30, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 46,000 | $360,180 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Y-mAbs Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2024 proxy (filed May 30, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-09-16 | Disposition to the issuer derivative | — | 63,500 | — | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 15,900 | — | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 170,000 | — | 0 |
| 2025-09-16 | Disposition to the issuer derivative | — | 15,900 | — | 0 |
| 2025-09-16 | Disposition to the issuer | — | 77,800 | — | 0 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Y-mAbs Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Michael Rossi | President and Chief Executive Officer | $4,557,590 |
| Peter Pfreundschuh · this page | Treasurer and Chief Financial Officer | $2,504,717 |
| Thomas Gad | Founder, Chief Business Officer and Vice Chairman of the Board of Directors | $2,075,163 |
Peter Pfreundschuh's compensation dossier, Y-mAbs Therapeutics
You have read Peter Pfreundschuh's totals and holdings. The dossier adds each equity grant Y-mAbs Therapeutics disclosed for Peter Pfreundschuh and Y-mAbs Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Y-mAbs Therapeutics compensation record
free company briefThis page is one person within Y-mAbs Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Y-mAbs Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Y-mAbs Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Y-mAbs Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order YMAB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.